Despite the coming of age of cancer immunotherapy, clinical benefits are still modest. An important barrier to successful cancer immunotherapy is that tumors employ a number of mechanisms to facilitate immune escape, including the production of anti-inflammatory cytokines, the recruitment of regulatory immune subsets, and the production of immunosuppressive metabolites. Significant therapeutic opportunity exists in targeting these immunosuppressive pathways. One such immunosuppressive pathway is the production of extracellular adenosine by CD73, an ectonucleotidase overexpressed in various types of cancer. We hereafter review the biology of CD73 and its role in cancer progression and metastasis. We describe the role of extracellular adenosi...
CD73 is a cell surface ecto-5′-nucleotidase, which converts extracellular adenosine monophosphate to...
CD73 is a cell surface enzyme that suppresses T cell-mediated immune responses by producing extracel...
Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important ...
Tumors use several strategies to evade immunosurveillance. One such mechanism is the generation of a...
Introduction: Cancer cells apply various mechanisms to induce and enhance immune escape. The complex...
Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth. We perfor...
High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as w...
Increasing evidence supports the occurrence of an intriguing link between tumor onset and developme...
In recent years, cancer immunotherapy made significant advances due to a better understanding of the...
CD73 is an ectonucleotidase able to catabolize 5′-adenosine monophosphate (AMP) into adenosine at th...
The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immuno...
The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor...
CD73 is a cell surface 5′-nucleotidase that converts AMP to adenosine, an immune suppressive molecul...
CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine....
CD73 is a cell surface ecto-5′-nucleotidase, which converts extracellular adenosine monophosphate to...
CD73 is a cell surface enzyme that suppresses T cell-mediated immune responses by producing extracel...
Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important ...
Tumors use several strategies to evade immunosurveillance. One such mechanism is the generation of a...
Introduction: Cancer cells apply various mechanisms to induce and enhance immune escape. The complex...
Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth. We perfor...
High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as w...
Increasing evidence supports the occurrence of an intriguing link between tumor onset and developme...
In recent years, cancer immunotherapy made significant advances due to a better understanding of the...
CD73 is an ectonucleotidase able to catabolize 5′-adenosine monophosphate (AMP) into adenosine at th...
The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immuno...
The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor...
CD73 is a cell surface 5′-nucleotidase that converts AMP to adenosine, an immune suppressive molecul...
CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine....
CD73 is a cell surface ecto-5′-nucleotidase, which converts extracellular adenosine monophosphate to...
CD73 is a cell surface enzyme that suppresses T cell-mediated immune responses by producing extracel...
Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important ...